ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
1 hedge funds and large institutions have $2.24K invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 11 closing their positions.
13.99% less ownership
Funds ownership: 14.01% → 0.02% (-14%)
92% less funds holding
Funds holding: 12 → 1 (-11)
100% less capital invested
Capital invested by funds: $1.03M → $2.24K (-$1.03M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 11
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Focus Partners Wealth
Boston,
Massachusetts
|
-$348K |
| 2 |
Jane Street
New York
|
-$346K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$271K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$29.7K |
| 5 |
Morgan Stanley
New York
|
-$13.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Osaic Holdings
Scottsdale,
Arizona
| $2.24K | -$5.64K | -617 | -80% |
|
|
2
Focus Partners Wealth
Boston,
Massachusetts
| – | -$348K | -36,879 | Closed |
|
|
3
Jane Street
New York
| – | -$346K | -36,741 | Closed |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$271K | -28,710 | Closed |
|
|
5
UBS Group
Zurich,
Switzerland
| – | -$29.7K | -3,147 | Closed |
|
|
6
Morgan Stanley
New York
| – | -$13.7K | -1,448 | Closed |
|
|
BBPWM
7
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| – | -$6.82K | -723 | Closed |
|
|
NFSG
8
Newbridge Financial Services Group
Boca Raton,
Florida
| – | -$2.83K | -300 | Closed |
|
9
Wells Fargo
San Francisco,
California
| – | -$2.36K | -250 | Closed |
|
|
NA
10
NewEdge Advisors
New Orleans,
Louisiana
| – | -$1.42K | -150 | Closed |
|
11
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -82 | Closed |
|
|
DF
12
Dunhill Financial
London,
United Kingdom
| – | -$2.41K | -62 | Closed |
|
CNCR Hedge Fund Activity: Q2 2025 in Review
1 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q2 2025, worth a combined $2.24K — down 100% from $1.03M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CNCR and 0 opened new positions — a net loss of 11 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Focus Partners Wealth, exiting entirely with an estimated $348K sold.
- 1 institutional investor held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q2 2025, down from 12 in Q1 2025.
- Funds reported $2.24K of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q2 2025, down 100% quarter-over-quarter.
- 0 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q2 2025 and 11 closed out, a net change of -11 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q2 2025 was Focus Partners Wealth, an estimated $348K sold.
Based on aggregated 13F filings for Q2 2025.